17:00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing, Christoph Zielinski, Vienna

Transcription

1 8 th Chinese German Lung Cancer Forum Dresden, Germany, September 8-10, 2016 Precision oncology in lung cancer Thursday, September 8, :00 17:45 Meet-the-Professor Immuno-Oncology Fan Yang, Beijing, Christoph Zielinski, Vienna 18:00 18:45 Meet-the Professor Molecular Pathology Caicun Zhou, Shanghai, Mauro Papotti, Torino Friday, September 9, :30 Welcome address Moderation: Yi-Long Wu, Guangzhou, Christian Manegold, Mannheim Xiao Zhou, Shanghai, Jacek Niklinski, Bialystok, Rudolf M. Huber, Munich, Jürgen Wolf, Cologne 09:00 Tobacco Control Xin Wang, Beijing, Lothar Pilz, Mannheim E-cigarette aerosol and nicotine exposure Manfred Neuberger, Vienna Smoking cessation in young people Anneke Bühler, Munich Tobacco control: The Chinese policy Xin Wang, Beijing 09:45 Pathology/Molecular biology Jiuwei Cui, Changchun, Martin Sos, Cologne New generation sequencing techniques Lukas Heukamp, Cologne Diagnostic issues: Cytology, tissue, liquid biopsy Agata Pilaszewicz-Puza, Bialystok

2 Molecular testing in China Jiuwei Cui, Changchun 10:30 Coffee break 10:45 Lung Cancer Screening/Innovative Imaging Jie Hu, Shanghai, Manfred Neuberger, Vienna Economics and management of lung disease Larissa Schwarzkopf, Munich Lung cancer screening based on modern imaging Jochen Dormeier, Erlangen Modern lung cancer staging Sonja Sudarski, Mannheim New PET Tracer Björn Wängler, Mannheim Lung cancer screening in China Jie Hu, Shanghai 11:45 Radiotherapy in lung cancer Zhengfei Zhu, Shanghai; Frank Giordano, Mannheim; Interaction between targeted agents and radiotherapy Anna Wrona, Gdansk Current issues in lung cancer radiotherapy in China Zhengfei Zhu, Shanghai Interventional radiology Michael Kostrzewa, Mannheim, Radiotherapy of brain metastasis: innovative approaches Frank Giordano, Mannheim 12:45 Lunch

3 13:45 Surgery Keneng Chen, Beijing; Eric Rößner, Mannheim Cross-border surgery of thoracic, plastic-reconstructive, and upper GI surgeons Peter Hohenberger, Mannheim Precision management of stage III NSCLC: The surgeon s position Michael Rolf Müller, Vienna Current issues in lung cancer surgery Keneng Chen, Beijing VATS, CATS, and RATS for diagnosis and treatment of lung cancer Eric Rößner, Mannheim Personalized lung cancer surgery contributes to precise medicine Wenzhao Zhong, Guangzhou 15:15 Biostatistics/Clinical Trials/Legal aspects Yi-Long Wu, Guangzhou, Lothar Pilz, Mannheim Clinical trials in lung cancer 2016: Considerations for precision medicine Lothar Pilz, Mannheim Clinical Trials in China: Contribution in global drug development Yi-Long Wu, Guangzhou Conflict preparation and conflict solution in medical environments Karl Brandt, Hamburg 16:00 Immunotherapy Yusong Zhang, Suzhou; Florian Kron, Cologne Is there still room for vaccines in lung cancer therapy? Marcin Moniuszko, Bialystok Checkpoint inhibitors in lung cancer therapy Jürgen Wolf, Cologne Immune checkpoint inhibitors: Costs effective strategies Florian Kron, Cologne

4 16.45 Coffee break 17:00 MicroRNA in thoracic oncology; Nico van Zandwijk, Sydney; Marcin Moniuszko, Bialystok Micro-RNA expression in lung cancer Urmo Võsa, Tartu Novel molecular therapeutic possibilities for lung cancer Anna Rusek, Bialystok MicroRNA based therapy in thoracic tumors personal experience Nico van Zandwijk, Sydney Chinese experience with microrna in thoracic oncology Fengying Wu, Shanghai 18:00 Uncommon thoracic tumors Xiaohui Chen, Fujian; Monika Serke, Hemer Role of surgery in SCLC Miroslaw Kozlowski, Bialystok ProGRP as a biomarker for clinical response evaluation in SCLC Thomas Muley, Heidelberg Treatment of SCLC: Chinese experience Xiance Jin, Wenzhou Malignant pleural mesothelioma precision oncology in 2016 Monika Serke, Hemer Thymoma and thymic carcinomas a critical review of WHO classification Alexander Marx, Mannheim

5 19:00 Management of advanced NSCLC Caicun Zhou, Shanghai; Robert Pirker, Vienna Personalized first-line therapy in 2016 Robert Pirker, Vienna Targeted therapy in China Fan Yang, Beijing Issues of drug resistance in targeted therapy Martin Sos, Cologne New anti-angiogenic agents in second-line therapy: Ramucirumab, nintedanib Rudolf M. Huber, Munich Treatment of advanced squamous cell carcinoma of the lung Jie Hu, Shanghai Treatment strategies after progression of first-line therapy Yusong Zhang, Suzhou 20:30 Housekeeping notes Christian Manegold, Mannheim Saturday, September 10, :00 08:00 Meet-the-Professor Radiotherapy: Hong Zhao, Beijing, Frank Giordano, Mannheim 08:00 Young Investigators Session Sabine Zöchbauer-Müller, Vienna; Yi-Long Wu, Guangzhou Surgery for multiple primary lung cancer Xiaohui Chen, Fujian Mutual relationship between cancer and immune cells Andrzej Eljaszewicz, Bialystok VEGFR-small molecular inhibitors in lung cancer Fengying Wu, Shanghai Overcoming resistance to EGFR-TKI therapy Sebastian Michels, Cologne Interaction of erythropoetine-receptor system and angiogenesis

6 Xiaoqing Liu, Munich Prognostic value of immune score in resected NSCLC Julia Stump, Munich 10:00 Closing remarks Caicun Zhou, Shanghai; Christian Manegold, Mannheim